# Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis

> **NCT07388420** · NA · RECRUITING · sponsor: **General Hospital of Shenyang Military Region** · enrollment: 40 (estimated)

## Conditions studied

- Hypertriglyceridemia Induced Acute Pancreatitis

## Interventions

- **DRUG:** Evolocumab 140 MG/ML [Repatha]
- **DRUG:** Conventional lipid-lowering therapy

## Key facts

- **NCT ID:** NCT07388420
- **Lead sponsor:** General Hospital of Shenyang Military Region
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-02
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07388420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07388420, "Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07388420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*